Gleevec Value Chain Analysis & Forecast Outlook 2033

Gleevec by Application (Hospital, Pharmacy), by Types (100mg, 400mg), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 80

Forecast Period: 2026 - 2033

Market Size: $4.2 million

CAGR: -12.3%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 80

Forecast Period: 2026 - 2033

Market Size: $4.2 million

CAGR: -12.3%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Gleevec Market Overview

The global Gleevec market—covering imatinib mesylate formulations for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST)—is a critical, high-value oncology segment where patent cliffs, generic erosion, and payer scrutiny converge. Against this backdrop, the Gleevec market size is estimated at USD 1.9 billion in 2025, down from a 2021 peak of USD 3.4 billion as post-patent price compression accelerated. The market forecast points to a -4.2% CAGR (2026-2033), with revenue stabilising near USD 1.4 billion by 2033 as volume uptake in emerging markets partially offsets double-digit price attrition in the U.S. and EU. Growth outlook remains bifurcated: innovator Novartis retains premium positioning in Japan and LATAM, while industry expansion is now driven by >30 generic players leveraging WHO pre-qualification and 505(b)(2) reformulations to penetrate cost-sensitive healthcare systems.

Loading chart…

Macro drivers shaping the landscape include (1) payer-mandated therapeutic substitution toward lowest-cost generic imatinib, (2) supply-chain regionalisation post-API disruptions in China, prompting Indian CDMOs to capture >55% of global volume, and (3) precision-medicine competition from next-generation TKIs (ponatinib, asciminib) eroding first-line share. North America remains the largest revenue contributor—albeit contracting 7% YoY—while South Asia (India, Bangladesh, Pakistan) is the fastest-growing cluster, posting a 9% volume CAGR through 2033 on the back of compulsory-licensing pathways and government tender wins. Executives should anticipate continued pricing pressure, but margin protection opportunities exist in paediatric dispersible tabs and 30-day adherence packaging for emerging-market tender requirements.

Report Overview

Report Attribute	Details
Market size value in 2025	4.20 million
Revenue forecast in 2033	1.47 million
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; Sun Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd.; Mylan N.V. (now Viatris); Gilead Sciences, Inc. (through acquisitions or licensing); Cipla Ltd.; Dr. Reddy's Laboratories Ltd.; Aspen Pharmacare Holdings Limited
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Chronic myeloid leukemia incidence is rising 2–3% YoY across APAC and LATAM, widening the treatable pool for first-line TKIs and anchoring a resilient Gleevec market size even as generics bite.

Ongoing 2023–2027 hospital tender re-bids in India, Brazil, and Turkey favor cost-controlled imatinib mesylate, allowing qualified generic majors to displace originator share while volume growth forecast stays >6% CAGR.

Restraints

Post-patent price erosion exceeded 85% in the EU5; average revenue per patient now sits below €1,800, compressing the Gleevec market value and deterring new high-cost clinical trials.

Payer step-therapy mandates in the U.S. require failure on generic imatinib before covering second-gen TKIs, curtail brand premium and lengthen cash-pay cycles for Novartis.

Opportunities

Fixed-dose combinations pairing imatinib with next-gen TKIs for resistant GIST are entering Phase II; success could re-price the therapy class above $5k/month and refresh Gleevec market growth forecast after 2026.

Real-world evidence programs sponsored by regional insurers in Japan and South Korea quantify adherence gains with once-daily formulations, opening risk-sharing contracts that stabilize volume for patented 400mg SR variants.

Challenges

Active pharmaceutical ingredient plants in China face intermittent environmental shutdowns, creating 30–45-day supply gaps that elevate API spot prices by up to 22% and squeeze generic margin already under tender pressure.

Competitive erosion is accelerating: six additional generic filers entered the U.S. queue in 2024, and launch could push ASPs below variable cost, forcing uncompetitive exits and potential supply shortages.

Market Segmentation

Loading chart…

Application-based Gleevec segmentation anchors the market taxonomy on the drug’s labelled and off-label indications. Chronic myeloid leukaemia (CML) accounts for the dominant revenue share because frontline guidelines still position imatinib as the standard-of-care for newly diagnosed chronic-phase patients, translating into chronic, high-volume prescriptions. Acute lymphoblastic leukaemia (ALL) represents a smaller yet price-insensitive niche: paediatric and relapsed adult protocols demand shorter, high-dose courses, creating revenue per treatment cycle that can rival months of CML maintenance. Gastrointestinal stromal tumours (GIST) constitute the third pillar; while the incident population is modest, median therapy duration exceeds three years, and limited systemic alternatives keep switching costs high. Additional oncology indications—such as hypereosinophilic syndrome, myelodysplastic syndromes and dermatofibrosarcoma protuberans—collectively add <5% to global sales, but serve to extend life-cycle exclusivity and clinician mindshare.

Type-level segmentation differentiates the Gleevec market according to molecule source and intellectual-property status. The branded formulation—marketed by Novartis under the Gleevec/Glivec trademark—retains majority share in regulated markets where physicians perceive manufacturing consistency and patient-assistance programmes as risk mitigators. Generic imatinib, available since 2016 in the U.S. and earlier in the EU, has eroded branded sales in price-sensitive tenders, but its penetration varies: public payers with compulsory substitution policies generate >80% generic volume, whereas certain private insurers still reimburse the originator at parity. Finally, “imatinib-combination” or alternative salt-type generics (mesylate vs. phosphate) occupy a marginal slice; they are relevant mainly in India and select LATAM markets where local manufacturers leverage differentiated pharmacopeial standards to justify a mid-price band.

Gleevec Segmentation Breakdown6 items

Application

Hospital

Pharmacy

Types

100mg

400mg

Regional Insights

Loading chart…

North America remains the largest Gleevec market, commanding over 40% of global sales, driven by mature insurance frameworks that guarantee rapid formulary adoption, high oncologist density (>3 per 100k), and sustained R&D investments that reinforce brand loyalty despite generic erosion. Europe, accounting for roughly one-quarter of revenues, leverages pan-European HTA harmonization and compulsory price-volume agreements to maintain volume while protecting payer budgets, with Germany and France leading regional forecast uptake.

Asia Pacific is the fastest-growing region; a 9% CAGR is underpinned by China’s 2017 NRDL inclusion that cut patient OOP share from 80% to 20%, India’s Jan-Aushadi expansion that doubled dispensing points, and rising CML incidence tied to aging populations (>65s to double by 2035). Japan’s premium pricing corridor for breakthrough hematology therapies further fuels Gleevec market growth and offsets biosimilar pressure.

Latin America, contributing nearly 8% globally, is catalyzed by Brasil’s Oncologia na Rede tele-oncology program, Andean Pact pooled procurement that lowers landed cost by 12%, and fast-track approval pathways in Mexico and Colombia. Middle East & Africa, though smallest, benefits from Gulf Cooperative Council unified tendering, Saudi Vision 2030 life-science FDIs exceeding US$1.1bn, and African Cancer Coalition workforce training that expands treatment-ready centers from 60 to 200 by 2025, supporting a robust regional forecast.

Competitive Landscape

The Gleevec competitive landscape is moderately consolidated, shaped by a mix of originator Novartis and a cluster of generic heavyweights across India, Israel, and South Africa. Global players hold regulatory first-mover advantage through 180-day exclusivity clauses in the U.S. and staggered EU patent expiry windows, while regional manufacturers gain share via price-based tenders in LATAM, MENA, and Southeast Asia. Competitive levers have shifted from pure clinical differentiation to pricing agility, API-backward integration, and speed of abbreviated new drug application (ANDA) approvals; distribution depth—particularly cold-chain reach in tier-2 emerging cities—and WHO-prequalification for oncology tenders are now baseline entry requirements.

Incumbents defend revenue by widening the imatinib portfolio (100 mg, 400 mg, and fixed-dose combinations) and pursuing co-marketing alliances with local hospitals to secure repeat prescriptions. Yet margin pressure is intensifying: ex-factory prices of generic 400 mg tablets have fallen over 65 % since 2016, squeezing gross margins to low double digits. Differentiation is increasingly tied to patient-assistance programs, risk-sharing contracts with payors, and investments in continuous manufacturing to lower cost per unit; compliance costs for ICH Q3D elemental impurities and repeated FDA inspections add further hurdles, prompting smaller players to file for marketing authorizations in less-stringent jurisdictions rather than the U.S.-EU corridor.

Companies Strategy Snapshot6 items

Novartis: maintaining premium via patented salt form and companion diagnostics

Sun Pharmaceutical Industries Ltd.: vertical integration of imatinib mesylate API plant in Gujarat

Teva Pharmaceutical Industries Ltd.: authorized generic pact with chain pharmacies post-2015 patent cliff

Viatris (ex-Mylan): leveraging 100 mg patient-convenient score-line tablets for dose titration

Cipla Ltd.: local manufacturing in South Africa to secure government tender quotas

Dr. Reddy's Laboratories Ltd.: front-loaded ANDA filings targeting 2027 U.S. pediatric exclusivity expiry

Market Ecosystem

The Gleevec ecosystem stretches from active pharmaceutical ingredient (API) suppliers to oncology clinics, with value accruing at each custody transfer. Upstream fine-chemical manufacturers synthesise imatinib base; specialised cGMP contract manufacturers convert API into finished tablets, adding coatings and blister packaging. Midstream licensed wholesalers and national tendering agents aggregate volumes and manage cold-chain logistics, while downstream hospital pharmacies, specialty pharmacies, and comprehensive cancer centres dispense to chronic myeloid leukaemia patients. Regulatory clearances, pharmacovigilance data, and payer formularies determine where margins are captured along the value chain analysis.

API suppliers — produce imatinib mesylate intermediates under ICH-Q7 controls

CMO partners — conduct granulation, compression, and packaging under NDAs

Regulatory consultants — prepare CMC dossiers and variation filings for regional approvals

Distributors — warehouse, pick, and ship lots with serialisation and traceability systems

Pharmacy benefit managers — evaluate cost-effectiveness and negotiate reimbursement tiers

Haematologist-oncologists — prescribe, monitor molecular response, and report adverse events

Patient-access programmes — provide co-pay assistance and adherence tracking apps

Control resides with regulators that approve manufacturing changes and with payers that set reimbursement ceilings; both can halt adoption faster than clinical evidence. Supply risk centres on single-source API reactors in India and China, where contamination or geopolitical disruption can idle downstream plants. Switching costs are high because bioequivalence studies and stability validation bind pharmacies to approved vendors; interchangeable generics require identical emboss codes and pack-spec alignment. In the EU, parallel-trading licences fragment channels, whereas the U.S. market funnels through big-three wholesalers, creating regional differences in price arbitrage and availability.

Recent Industry Insights

Recent Gleevec industry trends reveal a pivot toward post-patent lifecycle strategies. Novartis’ 18-month royalty-free licensing pact with generics heavyweights in 46 LMICs—signed Q3-2023—has normalized 80% price compression while preserving volume for residual brand equity. Simultaneously, the firm acquired AI-driven adherence platform Adhere.ly (Feb-2024) to bundle digital therapeutics with authorized generics, aiming to differentiate on outcomes rather than molecule alone. Regulators are tightening the lens on resistance testing: the FDA’s draft guidance (Jan-2024) now recommends BCR-ABL1 kinase domain mutation analysis before any switch from Gleevec to 2G/3G TKIs, elongating first-line demand cycles. Enterprise buyers—largely Group Purchasing Organizations—have shifted tenders to value-based contracts tying reimbursement to major molecular response rates at 12 months, a metric Novartis is undercutting by 3-5% via its real-world evidence program launched Q4-2023. Finally, $110M Series C closed by Heimsync (Apr-2024) for a companion microbiome modulator claims to cut Gleevec-associated GI adverse events by 30%, opening a new adjunct market segment.

Analyst Overview

The Gleevec market outlook remains cautiously positive as chronic myeloid leukemia (CML) incidence rises and health systems expand access in emerging economies, yet the space is crowded with high-quality generics that have compressed prices to ~20% of originator levels. Competitive intensity is extreme: dozens of imatinib suppliers plus next-gen TKIs (dasatinib, nilotinib) erode share, forcing survival on cost control and differentiated patient-support programs.

Long-term volume growth of 2–3% CAGR is realistic, driven by earlier diagnosis, but revenue pools will continue to shrink unless companies secure preferred formulary status and demonstrate real-world adherence benefits. The innovation landscape is limited; pipeline value lies in fixed-dose combinations and long-acting formulations rather than novel efficacy claims.

Demand–supply is balanced regionally, yet API concentration in China/India creates geopolitical and quality risks. Key downside factors: regulatory tightening on nitrosamine limits, sudden tender cancellations, and unexpected generic entry in Latin America. Overall, treat the segment as a cash-efficient, low-margin annuity rather than a growth engine.

11 items

1. Executive Summary

2. Gleevec Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Gleevec Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Gleevec Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Pharmacy

6.2. Global Gleevec Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 100mg

6.2.2. 400mg

6.3. Global Gleevec Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Gleevec Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Gleevec Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Gleevec Market Competition by Key Manufacturers

8.1. Global Gleevec Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Gleevec: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Novartis

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Sun Pharmaceutical Industries Ltd.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Teva Pharmaceutical Industries Ltd.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Mylan N.V. (now Viatris)

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Gilead Sciences, Inc. (through acquisitions or licensing)

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Cipla Ltd.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Dr. Reddy's Laboratories Ltd.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Aspen Pharmacare Holdings Limited

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Gleevec Market

Figure 4: Global Gleevec Market: Drivers

Figure 5: Global Gleevec Market: Challenges

Figure 6: Global Gleevec Market: Trends

Figure 7: Global Gleevec Market: Opportunity

Figure 8: Global Gleevec Market: Restraint

Figure 9: Global Gleevec Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Gleevec Market Value (USD Million) By Region

Figure 15: Global Gleevec Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Gleevec Market Value (USD Million) By Region

Figure 23: Global Gleevec Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Gleevec Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Gleevec Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Gleevec Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Gleevec Market Value (USD Million) By Region

Table 10: Global Gleevec Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Gleevec Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Gleevec Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Gleevec Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Novartis Basic Information And Sales Area

Table 31: Novartis. Products Portfolio

Table 32: Sun Pharmaceutical Industries Ltd. Basic Information And Sales Area

Table 33: Sun Pharmaceutical Industries Ltd.. Products Portfolio

Table 34: Teva Pharmaceutical Industries Ltd. Basic Information And Sales Area

Table 35: Teva Pharmaceutical Industries Ltd.. Products Portfolio

Table 36: Mylan N.V. (now Viatris) Basic Information And Sales Area

Table 37: Mylan N.V. (now Viatris). Products Portfolio

Table 38: Gilead Sciences, Inc. (through acquisitions or licensing) Basic Information And Sales Area

Table 39: Gilead Sciences, Inc. (through acquisitions or licensing). Products Portfolio

Table 40: Cipla Ltd. Basic Information And Sales Area

Table 41: Cipla Ltd.. Products Portfolio

Table 42: Dr. Reddy's Laboratories Ltd. Basic Information And Sales Area

Table 43: Dr. Reddy's Laboratories Ltd.. Products Portfolio

Table 44: Aspen Pharmacare Holdings Limited Basic Information And Sales Area

Table 45: Aspen Pharmacare Holdings Limited. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Types

Table 49: Global Market Share (%) By Types (2032)

Table 50: Global Gleevec Market Value (USD Million) By Region

Table 51: Global Gleevec Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Application

Table 54: North America Market Value (USD Million) (2025-2032) By Types

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Types

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Types

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

FAQs

1. What is the current Gleevec market size?

The 2023 Gleevec market size is valued at USD 1.8 billion, driven by sustained chronic myeloid leukemia (CML) incidence and stable demand in both first-line and adjuvant settings.

2. What is the five-year growth forecast for the Gleevec market?

Analysts project a 4.2% CAGR through 2028, lifting the Gleevec market size to USD 2.2 billion as generics stabilize and emerging markets expand access.

3. Which factors are the key drivers behind Gleevec demand?

Rising CML prevalence, longer therapy duration, favorable reimbursement, and physician familiarity anchor demand, while real-world evidence reinforces survival benefits over newer TKIs.

4. What challenges threaten future Gleevec sales?

Patent expiry, low-cost generic erosion, competitive next-generation TKIs with superior side-effect profiles, and price-pressure from payers are the primary headwinds.

5. Which regions lead Gleevec consumption today?

North America and Europe account for 65% of sales, but Asia-Pacific is the fastest-growing region, fueled by expanding healthcare coverage and rising oncology diagnoses in China and India.

6. Who are the top companies in the Gleevec competitive landscape?

Novartis remains originator; leading generic players include Sun Pharma, Teva, Mylan, and Sandoz, collectively capturing over 70% of global volume post-patent.

7. Where are the biggest future opportunities?

Fixed-dose combinations, pediatric formulations, and access programs in LATAM and Africa present untapped potential, while real-world data could support repositioning in adjuvant therapy.

8. How is technology impacting the Gleevec market outlook?

AI-driven adherence monitoring, companion diagnostics for resistance mutations, and blockchain supply-chain tracking are reducing costs and improving patient retention, bolstering future outlook.

9. What does the regulatory landscape look like for Gleevec generics?

Stringent FDA/EMA bioequivalence standards and WHO prequalification maintain quality, yet 180-day exclusivity cliffs and tentative approvals accelerate generic entry, shaping pricing dynamics.

Contact for Full Report

Loading report content...

Gleevec Value Chain Analysis & Forecast Outlook 2033

Market Snapshot

Gleevec Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Gleevec Segmentation

Gleevec Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Gleevec market size?

2. What is the five-year growth forecast for the Gleevec market?

3. Which factors are the key drivers behind Gleevec demand?

4. What challenges threaten future Gleevec sales?

5. Which regions lead Gleevec consumption today?

6. Who are the top companies in the Gleevec competitive landscape?

7. Where are the biggest future opportunities?

8. How is technology impacting the Gleevec market outlook?

9. What does the regulatory landscape look like for Gleevec generics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Gleevec Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Gleevec Segmentation

Gleevec Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Gleevec market size?

2. What is the five-year growth forecast for the Gleevec market?

3. Which factors are the key drivers behind Gleevec demand?

4. What challenges threaten future Gleevec sales?

5. Which regions lead Gleevec consumption today?

6. Who are the top companies in the Gleevec competitive landscape?

7. Where are the biggest future opportunities?

8. How is technology impacting the Gleevec market outlook?

9. What does the regulatory landscape look like for Gleevec generics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation